Global Cardiac Marker Testing Market Size Study & Forecast, by Product Type (Reagents and Kits, Instruments), by Biomarker Type (Troponin I and T, Creatine kinase-MB, Brain Natriuretic peptide, Other Cardiac Biomarkers), by Diseases (Myocardial Infarction

Global Cardiac Marker Testing Market Size Study & Forecast, by Product Type (Reagents and Kits, Instruments), by Biomarker Type (Troponin I and T, Creatine kinase-MB, Brain Natriuretic peptide, Other Cardiac Biomarkers), by Diseases (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), by End User, and Regional Analysis, 2023-2030

Global Cardiac Marker Testing Market is valued at approximately USD 4.02 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.4% during the forecast period 2023-2030. Cardiac marker testing involves analyzing specific biomolecules released into the bloodstream in response to heart-related conditions, aiding in the diagnosis and assessment of cardiovascular diseases. These markers aid in diagnosing acute coronary syndromes, heart attacks, and other cardiac disorders. The testing is performed through blood tests to measure marker concentrations, with elevated levels indicating heart muscle damage. Cardiac marker testing is vital for early diagnosis, risk assessment, treatment monitoring, and ruling out or confirming acute myocardial infarction. It plays a pivotal role in cardiovascular medicine, contributing to timely interventions and improved patient outcomes. The rising clinical studies for the identification of novel cardiac biomarkers, the increase in geriatric population and subsequent escalation in heart conditions globally, cohesive government initiatives for the diagnosis of cardiac diseases, as well as growing funding initiatives from public and private organizations are the most prominent factors that are propelling the market demand across the globe.

In addition, the surge in incidences of cardiovascular diseases is directly associated with the demand for cardiac marker testing, which, in turn, augments the market growth at a substantial rate. The World Health Organization (WHO) reports that, with an estimated 17.9 million deaths worldwide each year, Cardiovascular Diseases (CVDs) are the world's leading cause of mortality. In addition, 85% of these fatalities from cardiovascular disease are caused by heart attacks and strokes. As CVDs remain a leading cause of morbidity and mortality, the demand for diagnostic tools to identify and manage these conditions continues to grow. Furthermore, Ischemic Heart Disease (IHD) is a major cause of mortality worldwide, as per a study published in the Cureus Journal of Medical in July 2020 Science. Ischemic heart disease affects around 126 million individuals globally (1,655 per 100,000), or about 1.72% of the total population. It is predicted that there are more than 1,845 instances of ischemic heart disease per 100,000 individuals globally by 2030. Moreover, the ongoing research on novel cardiac biomarkers for cardiovascular diseases, as well as the soaring demand for Point-of-Care (POC) testing presents various lucrative opportunities over the forecast years. However, the technical issues related to sample collection and storage and several challenges associated with biomarker assay validation are hindering market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cardiac Marker Testing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the high cases of cardiovascular diseases, a rise in cardiac marker testing procedures, and the presence of well-established entities with robust portfolios in cardiac biomarker testing. Additionally, government backing for the exploration of new cardiac biomarkers is anticipated to provide further opportunities to the Cardiac Marker Testing Market across the region. Whereas, Asia Pacific is expected to grow at the fastest CAGR over the forecast years. The rise in the prevalence of Cardiovascular Diseases (CVD), an upsurge in testing procedures, advancements in healthcare infrastructure, and the widespread incorporation of advanced immunoassay technology in clinical laboratories are significantly propelling the market demand across the region. Furthermore, the Cardiac Marker Testing Market in the Asia Pacific is poised to benefit from the proliferation of local manufacturers providing testing products for cardiac markers and the expanding network of diagnostic laboratories in the region.

Major market players included in this report are:
F. Hoffmann-La Roche AG
Abbott Laboratories
Danaher Corporation
Siemens Healthineers AG
PerkinElmer, Inc.
BioMérieux SA
Becton, Dickinson and Company
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Tosoh Corporation

Recent Developments in the Market:
 In October 2023, BD announced that the company had received the FDA's approval for the utilization of its BD Vacutainer Troponin I Ultra test in point-of-care settings. This approval designates the BD Vacutainer Troponin I Ultra test as the pioneering and sole FDA-approved troponin test for on-the-spot diagnosis of Acute Myocardial Infarction (AMI).

Global Cardiac Marker Testing Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product Type, Biomarker Type, Diseases, End User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product Type:
Reagents and Kits
Instruments

By Biomarker Type:
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide (Bnp Or Nt-Probnp)
Myoglobin
High-sensitivity C-reactive protein (hs-CRP)
Other Cardiac Biomarkers

By Diseases:
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia

By End User:
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.